MRI in active surveillance â€" a modern approach
INTRODUCTION
Prostate cancer is the most common malignancy in men, with over 1,600,000 cases and 366,000 deaths annually worldwide (1) . Population screening using prostate specific antigen (PSA) has led to a decrease in cancer-related mortality but also to an increased detection of patients diagnosed with low-risk biopsy proven prostate cancer (2) . The impact of PSA screening on overall mortality remains unclear, and seems to differ depending on the population and strategy used (3) . The choice of treatment for a man with localised prostate cancer is determined by the risk of the cancer progressing, and patient preferences. Patients are commonly asked to balance the avoidance of side effects on active surveillance with a slight increase in the need for more intensive treatment, when choosing an initial management strategy for a new diagnosis of lower risk prostate cancer.
Risk stratification is based on different parameters such as clinical stage, PSA, Gleason score and an approximation of cancer volume (indicated by the number of positive cores and the maximum extent of cancer within a positive core at biopsy) (4) . In recent years, active surveillance has been increasingly adopted for conservative management of low and sometimes intermediate risk prostate cancer to avoid treatment until there is evidence of higher risk disease (5) . Published active surveillance protocols rely on PSA, digital rectal examination and biopsy results, and they differ by institution (5, 6) . The majority of them consider only low risk Gleason 3+3 disease, but some centres also allow men with lower intermediate risk features such as Gleason 3+4 disease (6,7).
There is evidence that multiparametric magnetic resonance imaging (mpMRI) in the setting of active surveillance for prostate cancer is being increasingly used (8) .
It is well known that the negative predictive value of high quality mpMRI for the detection of clinically significant cancer is very high (8) (9) (10) . Studies have also shown that the presence of a visible lesion on mpMRI in men on active surveillance for prostate cancer increases the likelihood of higher risk disease at subsequent biopsy (11, 12) .
In 2012 a systematic review of mpMRI targeted biopsies compared to standard biopsies in the diagnostic setting showed that MRI-targeted biopsies are at least as accurate at detecting clinically significant disease, and can do so with greater efficiency (fewer cores taken in fewer men) (13) . MRI-targeted biopsy was defined as any technique which used the information gained on the presence and location of a suspicious lesion on mpMRI, at the time of the biopsy.
The biopsy itself can be carried out using one of three methods, as set out by the START (Standards of Reporting for MRI-targeted Biopsy Studies) collaborative group (14) :
 In-bore biopsy, where diagnostic MRI images are fused with lower strength interventional MR images, and the biopsy is carried out in the MRI scanner  Visual registration, where the information on the MRI suspicious lesion is conveyed to the biopsy operator by means of a diagram or snapshotted image in the MRI data, and the biopsy is carried out using transrectal ultrasound  Software assisted registration, where the MRI lesion is fused with or overlaid on the real-time ultrasound image used at the time of biopsy More recently, Wegelin and colleagues assessed which of the different ways of using the mpMRI information at the time of biopsy was more accurate. (15) . In their review, they concluded that MRI-guided biopsies (all techniques combined) have higher detection rates of clinically significant prostate cancer compared to transrectal ultrasound guided biopsies on a per patient basis, with a lower rate of detection of insignificant disease. For the detection of clinically significant prostate cancer there was no difference in efficacy between the different MRI-guided techniques. They also noted that MRI-guided biopsies miss 10% of significant cancers, compared to 21% missed using a standard biopsy approach alone.
De Visschere and colleagues (16) have recently shown that men with normal findings on mpMRI (overall Prostate Imaging Reporting and Data System -PI-RADS -≤2) are at very low risk of having a clinically significant prostate cancer, with negative predictive values ranging between 63% and 91% for prostate cancer of any grade, and from 92% to 100% for clinically significant prostate cancer (depending on the definition used) in low-risk men (PSA <10 ng/ml, normal digital rectal examination, no family history). This could have implications for a re-biopsy strategy in men with low risk disease on active surveillance, who might be able to avoid or defer repeat biopsy if they are deemed to have no visible cancer on mpMRI.
It is also established that MRI-targeted biopsies are able to better characterise prostate cancer with regards to Gleason score and cancer burden (17, 18) . In some centres, mpMRI and MRI-guided biopsies are used as an additional testing method to look for evidence that would prompt a change to active management of prostate cancer (8) . For men with low risk cancer on initial standard biopsy who opt for active surveillance, they should be counselled to have additional MRI-targeted biopsies if the mpMRI shows a suspicious lesion which has not been demonstrated on biopsy. The risk of upgrading in men on active surveillance with non-visible cancer on mpMRI has been shown by one group to be low (8.3%) vs 41% in men with visible tumour on mpMRI (19) .
Another paper assessing the concordance of biopsy and mpMRI in men on active surveillance concluded that those men who had a concordant mpMRI and biopsy could safely avoid confirmatory biopsy, whereas those with an MRI lesion >1cm should be counselled to have an MRI-targeted biopsy (20) .
In the last few years the scientific community has shown an increasing interest in the use of mpMRI in active surveillance (21) (22) (23) . There is discussion about whether all of the potential mpMRI sequences should be used at all time points in men on active surveillance. Recent papers include systematic reviews, editorials, commentaries and original studies. In this report, we collate and discuss those papers -classified as original articles -that investigate the role of the different mpMRI sequences in men on active surveillance for prostate cancer.
Multiparametric MRI in active surveillance protocols
A detailed explanation of mpMRI of the prostate is beyond the purpose of this paper, but some technical concepts must be discussed in order to fully understand the studies on active surveillance that will be presented.
MpMRI refers to the use of different anatomical and functional imaging parameters, each of which investigates a specific aspect of the prostate gland.
1. T2-weighted imaging (T2-WI): this is the most useful technique to study the anatomy of the gland. The peripheral zone appears bright due to the high presence of glandular tissue, while the transitional zone shows a heterogeneous appearance with the presence of multiple stromal nodules made of compact muscle fibre bundles. Tumours on T2-WI show low signal intensity (i.e. darker than surrounding tissues) (24).
2. Diffusion-weighted magnetic resonance imaging (DW-MRI): this sequence assesses the free movement (i.e. the diffusivity) of water molecules within tissues. In prostate cancer, this results in a higher signal intensity (i.e. brighter than surrounding tissues) on long b-value sequences and a lower signal (dark areas) on the reconstructed apparent diffusion coefficient (ADC) map (25, 26 Two other important aspects of mpMRI of the prostate should be mentioned:
 Coils: mpMRI of the prostate is performed using a pelvic phased-array coil, with some institutions using an additional endorectal coil (30) . However, a recent study has shown that the use of an endorectal coil can be omitted in a prostate cancer detection setting (31) .
 Scoring system: the likelihood of clinically significant prostate cancer on mpMRI is commonly reported using a 1-5 likelihood scale. The PI-RADS scale is an internationally agreed set of criteria to determine the score (32) (33) (34) whereas the Likert scale is less prescriptive but allows an individual radiologist to give an overall impression of the likelihood of clinically significant disease. (35) .
The ability of mpMRI to rule out clinically-significant prostate cancer prior to diagnostic biopsy has been shown in the PROMIS study, a prospective, multi-centre trial conducted in the United Kingdom (36) . The study was conducted on 576 biopsy-naïve men, who underwent mpMRI followed by both transrectal ultrasound and transperineal template prostate mapping biopsy. This latter was used as reference standard. Clinically significant cancer was defined as Gleason score ≥ 4 + 3, or a maximum cancer core length 6 mm or more in any location. The negative predictive value in detecting clinically significant cancer was 89% for mpMRI and 74% for transrectal ultrasound biopsy (p<0.0001).
Additionally, the results from this study supports the idea that mpMRI, used as a triage test before first prostate biopsy, could reduce unnecessary biopsies by a quarter. The Authors suggest that mpMRI could be recommended to all men with an elevated serum PSA before biopsy, reducing the diagnosis of clinically insignificant disease and improving the detection of clinically significant cancers.
The negative predictive value of mpMRI demonstrated here has relevance for the application of mpMRI in active surveillance for prostate cancer. The UK National Institute for Health and Care Excellence (NICE) guidelines recommend the use of mpMRI at the start of active surveillance, and that it can be used either in addition to or instead of biopsy for repeat assessment during follow up (37) .
In a recent study by Tran et al. 207 men on active surveillance underwent MRIultrasound fusion biopsy, and 14% had pathological upgrading in the targeted cores that was not detected by systematic sampling (38) .
There is discussion about whether it might be appropriate to instigate active treatment based on mpMRI alone in men with biopsy proven prostate cancer on active surveillance, or whether a targeted biopsy must always be done prior to definitive treatment. Whilst biopsy to confirm any mpMRI findings is usually recommended, there are patients who could have opted for active treatment rather than active surveillance who will wish to avoid further biopsy prior to treatment (17) .
Evidence acquisition
In this paper, we have assessed those studies which have analysed the role of the different mpMRI sequences (T2, DWI, DCE and spectroscopy) in men on active surveillance for prostate cancer. We searched MEDLINE/Pubmed for manuscripts published from the inception of PubMed in 1971 to December 2017. The search terms used were (prostate cancer OR prostate adenocarcinoma OR prostatic carcinoma OR prostate carcinoma OR prostatic adenocarcinoma) AND (MRI OR NMR OR magnetic resonance imaging OR mpMRI OR multiparametric MRI) AND active surveillance. If it was not clear from the abstract whether the paper might contain relevant data, the full paper was assessed.
Overall, 425 publications were found. Seventy-one papers were related to the research question. We then excluded those falling in one of the following groups: i) review articles on active surveillance; ii) reports from consensus meetings, editorials, commentaries and case reports; iii) full text papers not in English. Twenty -five papers are included in the analysis. The literature search and study selection is displayed in Figure 3 .
Evidence synthesis
Among the 25 reports which were assessed in full, two (8%) had their main results based on T2-WI, fourteen (56%) on DWI, three (12%) on T2 and DWI, and six (25%) investigated more than two parameters of T2-WI, DWI, DCE and spectroscopy) (Fig. 3) .
We have collated the papers based on the sequences used.
T2-weighted imaging in active surveillance (Table 1) Two studies from our own institution report interesting results based on calculations made on T2-WI (39, 40) . Both reports are from a randomised, placebo-controlled trial that evaluates the effects of 0.5 mg daily dutasteride for 6 months on prostate cancer.
Men taking dutasteride are compared to those men on placebo. This is interesting in terms of the effect of dutasteride, but also for the use of repeat mpMRI in men on active surveillance, with the same set of sequences taken at baseline, 3 and 6 months in all men. The first paper (39) reported an average reduction in lesion volume of 36% on T2-WI in men on dutasteride. Conversely, in the placebo group there was an average increase in volume of 12% over the six-month period. The authors concluded that dutasteride was associated with a significant reduction in apparent prostate cancer volume on T2-weighted magnetic resonance imaging compared to placebo.
The other paper reported a retrospective review of the same cohort of men, looking at T2-relaxation time (a biomarker sensitive to tissue microenvironment) between baseline and 6-month mpMRI scans (40) . T2 relaxation times and T2-WI were not significantly influenced by the exposure to dutasteride. It was concluded that dutasteride may not impair the ability to measure tumour volume on T2-WI in men on active surveillance for prostate cancer.
Diffusion weighted imaging in active surveillance (Table 2) We found 14 studies whose main results are based on DWI findings, which are presented in Table 2 . The majority of them are retrospective studies, but five studies were conducted prospectively (27, (41) (42) (43) (44) . Five studies (27, 42, (45) (46) (47) (27, 43, 44, 50, 51) used an endorectal coil in the mpMRI protocol, and some studies had whole gland pathology in men with biopsies suitable for active surveillance as a reference standard (45) (46) (47) 52, 53) . One study (54) did not report the Gleason score prior to enrolment into active surveillance.
A closer look at Table 2 shows that the majority of the studies have been conducted on 3.0 T MRI scanners without an endorectal coil, and that 12 out of 14 (86%) report qualitative data from ADC calculations. As an example, our group at University College London has recently undertaken specific analyses on the effects of dutasteride on DWI (25) . We have observed that absolute changes in ADC and lesion conspicuity on DWI are significantly different between men on active surveillance taking daily placebo or dutasteride for 6 months: (-0.03 vs 0.08, p = 0.033) and (0.11 vs -0.16, p = 0.012), respectively. The same has been observed for percentage changes in these parameters:
(-2.27% vs 8.56% p =0.048) and (9.25% vs -9.89% p =0.013), respectively. Whilst dutasteride is not licenced for use in prostate cancer, it is not unusual for men on active surveillance to be taking a 5 alpha-reductase inhibitor for lower urinary tract symptoms, within the licence. With these men, it is worth remembering in clinical practice that the MRI conspicuity of prostate cancer may be reduced, and so having a lower threshold for biopsy or repeat biopsy in these men makes sense. Looking at the studies done, it is clear that DWI shows great potential in identifying men with higher risk disease who have been classified as low risk disease suitable for active surveillance on standard biopsy. The potential advantage of using T2-weighted imaging and diffusion (sometimes referred to as bi-parametric MRI) is the shorter scan time (compared to the addition of contrast), and the fact that there does not need to be a doctor on site to cover for the potential for an allergic reaction to contrast.
Studies reporting T2-WI and DWI in active surveillance (Table 3) Three studies report interesting results using combined data from T2-WI and DWI, and they are listed in Table 3 . All three studies (49, 55, 56) Use of multiple (at least 3 sequences) in men on active surveillance (Table 4) Six studies have assessed multiple MR parameters in men on active surveillance, and they are listed in Table 4 . Two studies (57, 58) included men according to PRIAS criteria. Turkbey et al. (60) have also provided compelling evidence that mpMRI can add important information to clinic-pathologic scoring systems. Two experienced radiologists evaluated T2-WI, ADC maps, DCE and spectroscopy images in consensus, in 133 men before radical prostatectomy and assigned an imaging score to each lesion. For segmenting the tumours, T2-WI, ADC maps and DCE images were used to determine tumour boundaries in combination, although the final calculations were made on T2-WI.
The authors concluded that MRI scoring system and dominant tumour volume measurements could be helpful in stratifying men suitable for active surveillance or active treatment.
One study (61) has compared mpMRI findings with a genomic prostate score based on a biochemical 17-gene expression signature. A 5-point scale of increasing suspicion of malignancy was used, and ADC was calculated from the lesions. As far as the genomic prostate score is concerned, no significant differences were seen for Gleason 3+3 (p = 0.179), but significant results were observed with Gleason 3+4 (p = 0.01). Mean ADC was weakly correlated with the genomic prostate score.
Hashimoto et al. (62) analysed the changes in prostate mpMRI features after testosterone replacement in 12 men on active surveillance and evaluated the ability of mpMRI to detect disease progression in this cohort. From the initial population (n = 16), three men discontinued the therapy for cancer progression (n = 1), increased haematocrit (n = 1) and explicit request (n = 1). The serum testosterone levels in the remaining twelve patients reached reference range at 6 months after the replacement therapy initiation. The authors of the paper reported that mpMRI findings were stable in those patients without progression at biopsy, while PI-RADS v. 2 score increased in two patients who were also upgraded (Gleason 3+4) on follow-up biopsy.
Conclusion
Active surveillance is a promising management strategy for low and intermediate risk 
